List view / Grid view
In this issue, find articles exploring why CRISPR is useful for high-throughput drug discovery, how targeting telomerase may lead to universal cancer vaccines and a new study to identify therapeutics that can be repurposed against COVID-19. Also included are features on neuroscience, organoids and antibodies.
MEPs have requested that the EU adopts new plans to phase out the use of animals in scientific research and testing, focusing on alternatives instead.
New research has explored the role of nasal bacteria to better develop intranasal vaccines for viruses such as COVID-19 and flu.
SARS-CoV-2 Spike gene mutants may be developed into immunogens for new vaccines against COVID-19, a study in hamsters has shown.
A nasal spray of the COVID-19 Vaccine Oxford/AstraZeneca was found to protect hamsters and monkeys against SARS-CoV-2 in an NIH study.
A research team have created a new strategy for developing an effective vaccine against a widespread form of tuberculosis.
CureVac and GSK's second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response in a pre-clinical study.
Researchers have been using artificial intelligence to study how the microbiome interacts with the human system to improve vaccine response.
Scientists from the University of Chicago discovered that the drug masitinib inhibits the replication of SARS-CoV-2 in mice.
A new “atlas” has been created in the US that charts how 152 different antibodies attack the SARS-CoV-2 Spike protein.
Scientists have used nanotechnology to develop personalised tumour vaccines which prevented cancer recurrence and metastasis challenges in mouse models.
Researchers in Australia have discovered a new site on the COVID-19 Spike protein that could be targeted by an anticoagulant drug.
A metabolic control pathway that regulates T follicular helper cells could enhance vaccine effectiveness, including those that protect against COVID-19.
A new mRNA-based vaccine has demonstrated success at protecting against multiple coronaviruses in pre-clinical studies.
A new mRNA vaccine based on the malaria circumsporozoite protein was shown to elicit a robust immune response in mice.
